Phone: 203-315-1222
Fax: 203-488-7838
Website: http://www.cellulargenomics.com

Contact(s)
Randall Halcomb, Director, Medicinal Chemistry

General Information
On July 8, 2010, CGI Pharmaceuticals, Inc. became a wholly-owned subsidiary of Gilead Sciences, Inc.

CGI Pharmaceuticals, Inc. (CGI) is a drug discovery and development company that is dedicated to developing breakthrough kinase inhibitor therapeutics for large unmet medical needs across a broad range of diseases. CGI's lead current drug discovery and development programs address compelling, well-validated targets for major clinical indications in cancer, angiogenesis, and allergic/autoimmune/inflammatory diseases. Promising drug candidates representing potential breakthrough, first-in-class therapeutics, have been developed in two rapidly advancing programs. CGI's powerful HALO chemistry platform represents a highly effective system for the rapid advancement of drug discovery programs from hit identificat8ion through lead optimization and into clinical development. Likewise, CGI's proprietary chemical genetics technologies have multiple applications throughout all phases of the drug discovery process and enhance CGI's state-of-the-art drug discovery and development capabilities.

Back